
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio Inc is advancing its pipeline of genetic medicines aimed at treating rare, monogenic CNS disorders, with promising interim data from the upliFT-D study indicating sustained increases in key biomarkers such as CSF PGRN. The company’s proactive approach to amending trial protocols suggests a potential for earlier intervention in disease progression, which may enhance treatment benefits for patients. Furthermore, the strategic design for accelerated regulatory approval based on biomarker endpoints presents significant opportunities for reducing trial timelines and driving future growth in the genetic medicines sector.
Bears say
Passage Bio Inc faces several significant challenges that contribute to a negative outlook on its stock. There are concerns regarding potential delays in clinical timelines, particularly for its pipeline products PBGM01 and PBFT02, which could be exacerbated by unforeseen safety issues or lower-than-expected efficacy, directly impacting market sentiment and leading to downward revisions of financial estimates. Furthermore, the company's reliance on sufficient manufacturing capacity raises additional regulatory risks, which, if not managed effectively, could materially constrict forecasts and impede overall growth potential.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares